Drugs / Na-APR-1 (M74)
Na-APR-1 (M74)
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02839161 | Jan 2017 → Dec 2018 | hookworm infectious disease | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02126462 | Nov 2014 → Feb 2016 | hookworm infectious disease | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01717950 | Sep 2013 → Jun 2015 | hookworm infectious disease | Baylor College of Medicine | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Na-APR-1 (M74) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02839161 ↗ |
| Known as | Na-APR-1 | “Two hookworm vaccine candidates, Na-GST-1 and Na-APR-1, formulated with Glucopyranosyl Lipid A (GLA-AF) adjuvant” PMID 34597297 ↗ Oct 2021 |
| Known as | Necator americanus aspartic protease-1 | “Necator americanus aspartic protease-1 (Na-APR-1) and N americanus glutathione S-transferase-1 (Na-GST-1) are involved in the digestion and detoxification of haemoglobin in the...” PMID 32926834 ↗ Sep 2020 |
| Modality | Vaccine | “The Na-APR-1 (M74) candidate vaccine contains the recombinant Na-APR-1 (M74) protein expressed by Nicotiana plants.” NCT01717950 ↗ |
| Route | Intramuscular | “Vaccines were administered intramuscularly on days 0, 28, and 180.” PMID 32926834 ↗ Sep 2020 |